Abiopharma

🔍 Murray Ciaran (Director)

Company: ICON PLC (ICLR)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 2,677 shares of Ordinary Shares (Direct)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 23,129.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 280 shares of Ordinary Shares at $162.72 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 22,849.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 305 shares of Ordinary Shares at $163.77 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 22,544.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Sold 1,880 shares of Ordinary Shares at $164.47 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 20,664.00 | transaction_form_type: 4 | Footnotes: F3, F6
• Sold 212 shares of Ordinary Shares at $165.51 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 20,452.00 | transaction_form_type: 4 | Footnotes: F3, F7
• Sold 2,677 shares of Restricted Share Units (Derivative)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1, F1
• Acquired 2,047 shares of Restricted Share Units (Derivative)
  Date: 2026-08-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,047.00 | transaction_form_type: 4 | Footnotes: F2, F8, F8, F8

Footnotes:

• F1: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026.
• F2: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting.
• F3: The Reporting Person sold all shares that vested on August 10, 2026, including shares to cover tax withholding obligations in connection with the vesting of compensatory equity awards.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $162.08 to $163.0799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $163.15 to $164.1499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $164.16 to $165.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $165.16 to $166.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
• F8: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027.
• REMARKS: Due to the issuer's status as a foreign private issuer pursuant to Rule 3a12-3(b) under the Securities Exchange Act of 1934 (the "Act"), the reporting person's transactions in the issuer's equity securities are exempt from Sections 16(b) and 16(c) of the Act.